Navigation Links
An ideal therapy for peptic ulcer disease
Date:11/11/2008

Since the discovery of the etiological role of Helicobacter pylori (H pylori) in peptic ulcer disease, its eradication became the main objective of therapy, and several treatment regimens were developed. Currently, triple therapy with omeprazole, amoxicillin, and clarithromycin remains the best therapeutic option. Despite its efficacy, 10% to 20% of the patients present with treatment failure, demanding alternative therapeutic regimes with variable success rates. The development of effective salvage treatments is of paramount importance in this situation.

The research team led by Jaime Natan Eisig, from Brazil addresses this question and this will be be published on October 28; 2008 in the World Journal of Gastroenterology.

The therapeutic regimen consisted of 20 mg omeprazole, 240 mg colloidal bismuth subcitrate, 1000 mg amoxicillin, and 200 mg furazolidone, taken twice a day for seven days. Patients were considered as eradicated when samples taken from the gastric antrum and corpus twelve weeks the end of treatment were negative for H pylori (rapid urease test and histology). Safety was determined by the adverse effects.

In this study, fifty one patients were enrolled. The eradication rate was 68.8% (31/45). Adverse effects were reported by 31.4% of the patients, and these were usually considered to be slight or moderate in the majority of the cases. Three patients had to withdraw from the treatment due to the presence of severe adverse effect. Their result indicated that the association of bismuth, furazolidone, amoxicillin and a proton-pump inhibitor is a valuable alternative for peptic ulcer patients.


'/>"/>

Contact: Lai-Fu Li
wjg@wjgnet.com
0086-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1

Related medicine news :

1. Jenny Craig Announces Finalists for the 2008 Ideal Size Contest
2. Through-Wave Ultrasound: Effective, Economical and Ideal for Breast Imaging, Biopsy
3. The Neuropathy Associations Scientific Research Grants Focus: Autoimmune and Chemotherapy-Induced Neuropathies
4. Sale of Enzymatic Therapy, Inc. to Natures Way Holding Company Finalized
5. Ellex Announces Six-Month Results on Retina Regeneration Therapy
6. ESF workshop makes major advance in cancer radiotherapy
7. 5th Annual Global Conference on Stem Cell Therapy to be held Jan. 13-16, 2009 in NYC
8. New Study Demonstrates Cost Effectiveness of NeuroStar TMS Therapy(R) in the Treatment of Depression
9. Hormone therapy helps short children grow up
10. Therapy may block expansion of breast cancer cells
11. TomoTherapy Completes Acquisition of Linear Accelerator Manufacturer in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Maryland (PRWEB) , ... December 06, 2016 , ... ... announced the launch of a Kickstarter crowd funding campaign ( http://kck.st/2g3a1so ) for ... health active alerts and even taking an EKG from the watch while sharing ...
(Date:12/6/2016)... ... December 06, 2016 , ... Specialty ... newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol for Great ... understand the scope of their EHS regulatory obligations and rapidly collect, share, archive, ...
(Date:12/5/2016)... ... ... What: Shriners Hospitals for Children, with the help of Dimension Data, will bring ... monitor and web-enabled camera. Santa visits with children through Dimension Data’s program to connect ... is where the video connection to the North Pole will stream. Much like children ...
(Date:12/5/2016)... ... December 05, 2016 , ... SyncDog, Inc., the leading ... magazine, a leading online tech news platform connecting technology innovators with news, experience, ... explores the state of enterprise mobility security today, and how the SyncDog SentinelSecure™ ...
(Date:12/5/2016)... ... December 05, 2016 , ... Progressive Laboratories™ is ... and glutathione to enhance production of nitric oxide (NO). , NitroGenesis Pro™ is ... produce NO twice as effectively and sustains NO blood levels twice as long ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... GAINESVILLE and BOCA RATON, ... The Florida Institute for the Commercialization of Public ... it has finalized a funding agreement SegAna, LLC, ... technology developed at University of Central Florida. The ... publicly-funded research, and bridges early funding gaps for ...
(Date:12/5/2016)... PUNE, India , December 5, 2016 ... Market by Treatment modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, ... 2021" published by MarketsandMarkets, the market is projected to reach USD ... at a CAGR of 13.5% during the forecast period of 2016 ... ...
(Date:12/5/2016)... , Dec. 5, 2016   BIOTRONIK today ... study. The study evaluates the safety and feasibility of ... an office setting. BioMonitor 2 is an ... that is placed underneath a patient,s skin to help ... (fainting). Atrial fibrillation is a leading cause of stroke ...
Breaking Medicine Technology: